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Abstract
Objective and design Skin retention and penetration by
copper applied as glycyl-L-histidyl-L-lysine cuprate diace-
tate was evaluated in vitro in order to assess its potential for
its transdermal delivery as an anti-inﬂammatory agent.
Materials and methods Flow-through diffusion cells with
1c m
2 exposure area were used under inﬁnite dose condi-
tions. 0.68% aq. copper tripeptide as permeant was applied
on isolated stratum corneum, heat-separated epidermis and
dermatomed skin and receptor ﬂuid collected over 48 h in
4 h intervals using inductively coupled plasma mass
spectrometry to analyze for copper in tissues and receptor
ﬂuid.
Results The permeability coefﬁcient of the compound
through dermatomed skin was 2.43 ± 0.51 9 10
-4 cm/h;
136.2 ± 17.5 lg/cm
2 copper permeated 1 cm
2 of that tis-
sue over 48 h, while 97 ± 6.6 lg/cm
2 were retained as
depot.
Conclusions Copper as tripeptide was delivered in
potentially therapeutically effective amounts for inﬂam-
matory disease.
Keywords Absorption  Arthritis  Bioavailability 
Copper complex  Depot  Inﬂammation
Introduction
Acute and chronic inﬂammation are characterized by
changes in the metabolism of copper and by a pronounced
responsiveness to therapy with copper compounds [1, 2].
The copper content and ceruloplasmin activity of serum are
signiﬁcantly elevated above normal values in inﬂammatory
diseases in man and laboratory animals, and copper in
widely different chemical forms is used as therapeutic
agent in therapy for chronic and acute inﬂammation [2].
The rise in total serum copper measured in inﬂammation is
held to represent the natural anti-inﬂammatory (AI)
response of the organism itself. The responsiveness of
inﬂammatory disorders to copper supplementation noted
suggests that the control exerted by endogenous copper on
inﬂammation is susceptible to enhancement by exogenous
sources. When copper complexes were administered subcu-
taneously, the reduction in inﬂammation was proportional
to total amount of copper injected [3].
The present research seeks a viable transdermal alter-
native to what so far has been a therapy for inﬂammatory
disorders relying on intra-articular or intramuscular injec-
tion of drugs which can cause patient discomfort and
untoward side effects. Data on human skin penetration by
copper compounds is rare. Pirot et al. [4] determined the
Skin permeability (Kp) for copper sulfate and chloride at
3.2 and 2.3 9 10
-6 cm/h, respectively, for the pyrrolidone
carboxylate at 5.7 9 10
-5 cm/h. Using a model membrane
made of stratum corneum lipids, Mazurowska suggested
that copper peptides, and GHK-Cu in particular, might
permeate skin [5–7]. Experiments using skin models gen-
erally underestimate absorption since the composition of
model membranes does not reﬂect the stratum corneum, a
heterogeneous, multicomponent membrane [8–10]. Orth
[11] and Finkey [12] measured uptake of copper into
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123superﬁcial facial skin strata in vivo when applying glycyl-
L-histidyl-L-lysine copper cuprate, diacetate (GHK-Cu).
However, to date, bioavailability of copper was not studied
quantitatively using human skin ex vivo. Therefore, evi-
dence that copper does penetrate the skin in any form is so
far based on its observed effects only. Anti-inﬂammatory
(AI) activity by topical application of copper complexes
was shown in animals by Brown [1], and in man by
Sorenson [2], and has been extensively reviewed by
Milanino [13].
Chemical: Glycyl-L-histidyl-L-lysine copper cuprate, diacetate GHK-
Cu(Ac)2, Formula: C18H29CuN6O8
Criteria for optimal diffusivity of cupriphores are hard to
deﬁne due to the complexity of equilibria that zwitterions
are subject to in the variable systemic environments they
encounter upon diffusion. Earlier investigations, however,
help in the design of complexes of adequate pharmaco-
logical activity. Those include:
• Copper derivatives of well-known antiarthritic drugs,
including steroidal and nonsteroidal AI agents. The
copper complexes of those drugs have been found to be
active or more effective AI agents than the parent drugs
[14].
• The AI effect of copper is non-speciﬁc with respect to
inﬂammatory pathologies and is enhanced by exoge-
nous sources [13].
• AI activity of exogenous copper sources is independent
of ligand [15]. On topical administration, copper
complexes are subject to dynamic ligand exchange in
the process of diffusion through skin [16]. Thereby,
copper oxidation state can change from monovalent to
divalent to the elemental state, and the original complex
administered topically is likely to differ from the
complex which subsequently forms with endogenous
amino acids to act as an AI agent [17].
The function of copper ligands thus is to promote skin
penetration only, and this study evaluates skin penetration
of a nature-identical copper complex [18]. If therapeuti-
cally signiﬁcant, that is, if transdermal AI therapy can
be achieved, it may present an alternative to current
approaches involving intra-articular or intramuscular
injection, which can cause patient discomfort, particularly
in arthritic patients where long term therapy is employed.
Materials and methods
Materials
The permeant was GHK-Cu received from the ProCyte
Corp. (Kirkland, WA). It was not analyzed for stoichiom-
etric purity since, in several studies, copper complexes in a
physiological environment were subject to de-complexation
and rearrangement, depending on pH and complex stability
constants [11, 19–21]. Those investigations indicated
the presence of multiple species for GHK-Cu (e.g., tri-and
hexa-peptide) in solutions, together with copper-free
oligopeptide. Copper as a transition metal of variable oxi-
dation states has the ability to form complexes with
different geometries and stability. Here, the copper tripep-
tide is summarily referred to as GHK-Cu. Concentrations
are reported in terms of copper per ml of solution.
Experimental design
Copper penetration was studied using split thickness skin,
isolated stratum corneum and entire epidermis.
Tissue preparation
Human cadaver skin was obtained from the Northern
California Transplant Bank (San Rafael, CA) and stored in
a freezer (-20 C) until use. All experiments were per-
formed within 2 months after freezing. All subjects were
Caucasian, aged 21–53 years, and both genders were
represented.
Split thickness skin (entire epidermis with a portion of
the dermis) was obtained by use of a dermatome targeted to
500 lm and stored (-20 C) until use.
Entire epidermis, (isolated. epidermis incl. stratum cor-
neum), was obtained by heat separation (60 C) and stored
(-20 C) until use.
Isolated stratum corneum was obtained from isolated
epidermis which was placed on Whatman paper soaked in a
0.05% w/w trypsin Type III (from bovine pancrease, Sigma
Chemical, St. Louis, USA) solution in 0.15 M phosphate
buffered saline (PBS, pH 7.4, Sigma) for 2 h at 37 C.
Remaining trypsin activity was blocked by submerging the
stratum corneum sheet in 0.05% w/w trypsin inhibitor
Typed II (from soybean, Sigma Chemicals, St. Louis,
USA), then the stratum corneum sheet was washed twice in
puriﬁed water, dried and stored above silica gel at room
temperature.
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123Separation of epidermis (incl. stratum corneum) from
dermis following split thickness skin diffusion experiment
C (sep. epidermis): recovered split thickness skin was
placed on polyethylene ﬁlm, covered with polyethylene
ﬁlm and placed under an aluminum block heated to 65 C
for 90 s, allowing separated epidermis to be lifted from the
dermis.
Diffusion experiment
Replicates were run on tissue from the same donor. Glass
low-volume ﬂow cells with 1 cm
2 exposure area were kept
at 37 C. Receptor ﬂuid was collected over 48 h in 4 h
intervals. Cells were mounted in the wells of an aluminum
cell holder (Stratacor, Richmond, CA), whose internal
channels were perfused with water at 37 C from a circu-
lating water bath, and holders were mounted on a fraction
collector. Water containing 1 ml/l of gentamycin sulfate
solution (l00 mg/ml) was pumped through the cells at
approximately 2 ml/h. Tissues were cut into circles with a
biopsy punch (1 cm
2), mounted on the diffusion cells and
the donor chambers clamped in place.
To test for tissue integrity, prior to the experiment with
tissue discs clasped in place, the peristaltic pump was run
at 10 rpm, generating back pressure in the receptor cells
(ﬁve times the normal pressure) for 2 h to check for
leakers, which were eliminated.
About 1 ml of test solution was placed in the donor
chambers, closed with ground glass stoppers and sealed
with Paraﬁlm to prevent donor solution evaporation.
At completion, the content of donor cells were collected
with a pipette, the skin surface washed (3 9 2 ml) with
distilled water and the rinses saved in LSC vials with
polyethylene capliners (Perkin-Elmer, Shelton, CT).
Analytical methodology
For original copper levels, portions of isolated stratum
corneum, isolated epidermis, as well as split thickness
dermis were analyzed to determine the increment retained
there during diffusion. Following diffusion experiment C,
split thickness skin was also separated into epidermis and
dermis (entire separated epidermis and separated dermis)
for analysis of tissue depot formation in the experiment.
Experimental details and results are reported in terms of
copper, analyzed by inductively coupled plasma mass
spectrometry (ICP-MS).
Analyses were performed by DuPont Analytical Solu-
tions, Wilmington, DE. There, samples were prepared by
diluting 1:10 (volume/volume), using 2% HNO3 immedi-
ately prior to analysis by ICP-MS. The ICP-MS equipment
used was an Agilent 7500c, operated under helium colli-
sion gas mode. The instrumental detection limit was
\100 pg/ml copper. Standard solutions were prepared by
diluting a 1,000-lg/ml Cu stock solution with 2% HNO3.
Two separate (low concentration and high concentration)
six-point external calibration curves (r
2[0.999) were
used for quantitation of both copper isotopes (63 and 65
Cu) with 89Y used as an internal standard. The low con-
centration calibration curve was constructed from 1, 2, 5,
10, and 20 ng/ml Cu standards and the high concentration
calibration curve was from 20, 100, 1,000, 5,000, and
10,000 ng/ml Cu standards. The instrument was calibrated
using the ﬁve standards above, and the samples bracketed
between the standards without extrapolation either below
the calibration curve or above it.
Data analysis
Kp (cm/h) was calculated from steady-state ﬂux Jss
(lg/cm
2/h) of copper. Tissue copper levels reported from
diffusion experiments were corrected for endogenous
levels determined prior to the experiments.
Standard deviations (SD) were calculated by the XL
program.
Results
Skin permeability coefﬁcients (Kps) for the copper tri-
peptide ranged from 3 9 10
-7 cm/h through isolated
epidermis (Table 1, Exp. B) to 5.54 9 10
-3 cm/h through
isolated stratum corneum (Table 1, Exp. A).
Lag times measured from 2 h on isolated stratum cor-
neum and spilt thickness skin (Table 1, Exp. A, C), to 7 h
on isolated epidermis (Table 1, Exp. B).
Copper collected in the receptor ﬂuid in 48 h ranged
from 0.60 ± 0.21 lg/cm
2 or 0.006 ± 0.001% of the dose
through isolated epidermis (Exp. B; Table 2), to 136.2 ±
17.5 lg/cm
2 or 2.0 ± 0.31% through split thickness skin
(Exp. C, Table 2).
Amounts of membrane retention in stratum corneum
tissue were 290 ± 69 lg/cm
2, a 438-fold increase over
baselinelevels(Tables 2,3,Exp.A),andatotal96.9 lg/cm
2
inthecompletedermatomedskin(Table 2,Exp.C)basedon
analysis of the separated strata after diffusion through split
thickness skin.
Discussion
This study evaluated absorption and skin retention of a
copper tripeptide on separate skin compartments: the stra-
tum corneum, epidermis and split thickness skin.
The amount of copper deposited from the tripeptide in
the stratum corneum as well as in the entire epidermis and
Skin penetration of a copper tripeptide 81
123dermis appears remarkable. For instance, an about 400-fold
increase over baseline was found in the stratum corneum
alone. Such high tissue retention of copper may be attrib-
uted to intradermal decomplexation and re-binding to
various endogenous amino acids with higher nucleophilic
donor capacity than the original ligand.
Whether or not skin levels retained in the stratum
corneum and epidermis/dermis in the diffusion process
of drugs should be included in the overall estimation
of absorbed material, i.e., assessing whether permeant
retained in skin tissues eventually will become available
systemically, is an issue of ongoing discussions. Reservoir
formation in the course of in vitro studies, in particular, has
been addressed [22]. Retained drug may be lost to natural
desquamation, limiting its eventual systemic availability, to
be sure. On closer analysis, however, it was also found that
the fraction of chemical that sloughs off versus the part that
becomes systemically available depends on the ratio of lag
time to the turnover time for the stratum corneum [23].
Accordingly, at least 80% of the amount in the stratum
corneum will become available if the lag time for
penetration through the stratum corneum is less than about
16 h, which corresponds to 5% of the stratum corneum
turnover time of typically 14 days. Consequently, based on
our results where lag times ranged from 2 to 7 h, the
copper retained in the stratum corneum may become lar-
gely systemically available. As a result of the experiment
with dermatomed skin, by topical application of GHK-Cu
under the present conditions 200–250 lg/cm
2 copper
would become systemically available. Since the experi-
ment was conducted ex vivo, it is possible that even larger
amounts will be retained in the deeper dermal tissue there,
followed by penetration in vivo.
The permeation rate of GHK-Cu through stratum cor-
neum seems high, the highest of all three skin strata
studied. It seems consistent with a model of porous trans-
port, as appendageal penetration is considered to be one, if
not the predominant pathway for the diffusion of multi-
polar ions [24–26]. In addition, the high penetration level
through stratum corneum alone can be explained by the
fact that there was no tissue retention from underlying skin
that may have limited penetration.
Table 1 Copper skin penetration as function of skin strata from aq. GHK-Cu solution
Exp. Skin strata Kp 9 10
4 (cm/h) ± SD Flux (lg/cm
2/h) ± SD Lag time (h)
A Isolated stratum corneum (n = 3) 55.9 ± 13.2 38 ± 92
B Isolated epidermis (n = 3) 0.003 ± 0.0006 0.002 ± 0.0004 7
C Dermatomed skin (n = 8) 2.5 ± 0.51 1.7 ± .35 2
Table 2 Human skin penetration and retention of copper in function of skin strata after 48 h (lg/cm
2; percent of applied dose)
Exp. Skin strata Donor
recovered
Stratum corneum Total epidermis Dermis Receptor ﬂuid Total
recovered
A Isolated stratum
corneum (n = 3)
(79 ± 13) 290.3 ± 69
(4.0 ± 0.15)
NA NA 2,110 ± 589
(19.85 ± 3.9)
(98 ± 27)
B Isolated epidermis
(n = 3)
(94 ± 12) ND 59.7 ± 13.1
(1.0 ± 0.3)
NA 0.60 ± 0.21
(0.006 ± 0.001)
(95 ± 12)
C Split thickness
(n = 8)
91 ± 14 ND 1.0
a ± 0.4
(66.0 ± 6,6)
0.09 ± 0.01
(30.9
a ± 6.8)
136.2 ± 17.5
(2.0 ± 0.31)
(94 ± 7)
NA not applicable; ND not determined
a Separated following split thickness diffusion
Table 3 Copper reservoir in skin layers versus original levels from 0.68% aq. GHK-Cu at 48 h
Skin compartment Cu at 0 h (lg/cm
2)C u a t 4 8 h ( lg/cm
2) Increase vs. 0 h
Isolated SC (Exp. A) 0.68 ± 0.28; n = 3 290 ± 69; n = 3 4389
Isolated Epi (Exp. B) 0.37 ± 0.17; n = 3 61.1 ± 7.0; n = 3 1659
Dermatomed skin (Exp. C) 1.72 ± 0.47; n = 85 3 ± 8.1; n = 83 1 9
Separated epidermis
a 0.37 ± 0.7; n = 8 66.7 ± 7.89; n = 8 1809
Separated dermis
b 1.72 ± 0.27; n = 8 27.63 ± 8.83; n = 81 6 9
a Separated following split thickness diffusion; total epidermis
b Dermis separated from split thickness skin following the diffusion experiment
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123The high hydrophilicity of the copper tripeptide (pseudo
log Pow =- 4.5, quotient sat. n-octanol/sat. aqueous
solution),
1 is reconcilable with shunt penetration typical for
highly hydrophilic solutes such as salts. Signiﬁcant pene-
tration through appendages can occur within minutes
following exposure, in contrast to non-appendageal path-
ways [27–30].
However, the Kps of GHK-Cu through epidermis and
dermatomed skin were lower at about one order of mag-
nitude. Restriction of the pore area may cause the
discrepancy in the diffusion constant. This suggests, in fact,
that the diffusion pathway for copper penetration is
restricted as compared to stratum corneum alone.
Skin retention and permeation by metal complexes is not
often investigated, and our observations on the subject of a
copper tripeptide merit more detailed discussion.
Copper is an essential trace element, critical for a
variety of biological processes; for hemoglobin synthesis,
enzyme activation, (i.e., superoxide dismutase), or more
generally as a key component of mitochondrial, cytoplas-
mic and nuclear enzyme systems [31].
It is a key factor in the production of collagen and
elastin [11, 12, 18], and the AI activity of numerous copper
complexes is well documented [13, 32]. Such activity was
greater than either treatment with inorganic copper salts or
the complexing agents alone: while many among the parent
compounds or ligands were inactive in test models of
inﬂammation even at larger screening doses, in coordina-
tion with copper they were active. The compounds thus
investigated include copper complexes of well-known
antiarthritic drugs, including steroidal and nonsteroidal
anti-inﬂammatory drugs: niﬂumic acid, D-penicillamine,
hydrocortisone, dexamethasone, dimethylsulfoxide, clopirac,
ketoprofen, (?)-naproxen, indomethacin, mefenamic acid,
diclofenac, ibuprofen among a number of others. The copper
complexes of those drugs have been found to be more effec-
tive anti-inﬂammatory agents than the parent drugs [33, 34].
Acute or chronic inﬂammation induces a net increase of
total copper in blood, synovial ﬂuid and inﬂamed areas,
mobilized from endogenous stores [13]. Chronic inﬂam-
mation may lead to depletion of copper stores, implying the
need for exogenous copper supply in order to effectively
cope with the inﬂammatory pathologies. While copper
complexes are commonly administered by injection, the AI
activity of subcutaneous administration of copper com-
plexes in animals was also shown to be proportional to total
amount of copper injected [34].
The present study indicates that topical administration of
copper in form of the tripeptide may offer an effective
alternative to injection. Since a realistic dimension for
topical application of GHK-Cu as patch may cover 10 cm
2
of skin, based on our results 2.33 mg of copper would
become available over 48 h. This may be compared to a
subcutaneous injection of 300 mg/kg of copper aspirinate
in rats without adverse effects, while it proved effective in
treating experimental subplantar edema even at a dose of
10 mg/kg.
When administering copper to the organism, its toxicity
should be addressed.
There is ample evidence that the copper ions released
will be subject to the highly efﬁcient homeostatic control in
eukaryotic organisms that prevents its circulation at unto-
ward levels. Levels of free ionic Cu, a relatively toxic
metal, are moderated to the minimum levels sufﬁcient for
physiologic needs, reported in the range of 10
-11 to 10
-19
mol estimated in plasma, by binding to ceruloplasmin
and metallothionein [35, 36]. The dynamic equilibrium
between ceruloplasmin and metallothionein stored in liver
tissue prevents toxic accumulation of free copper ion in
mammals [37]. That hepatic reservoir is released slowly
back into the blood as ceruloplasmin and copper metallo-
thionein in response to inﬂammation due to injury or
arthritis [38]. The average level of bound copper in human
control plasma is 1.12 lg/ml [39]; in arthritic patients it is
1.40 lg/ml [40]. A therapeutically effective copper level in
inﬂammation cannot be assessed in deﬁnite terms, how-
ever, because copper status induced in response to
inﬂammatory diseases in humans varies depending on
target organ [13].
In contrast to injection, in topical application the skin
forms a natural barrier which controls drug release over an
extended period, under approximately steady conditions
over a period of days. Flux, and not elimination from the
skin surface seems to be the limiting step, and repeated
dosage may result only in a build-up on the surface, pos-
sibly without signiﬁcantly affecting the kinetics.
Both historical and more recent investigative data
illustrate the safe exposure to exogenous copper as metal,
as its salts, or in complex form. Records on human expo-
sure to copper and its beneﬁts date back to prehistoric times
[41, 42]. As an example, in current medical practice copper
histidinate is administered intravenously to children suf-
fering from Menke’s disease (a.k.a. kinky hair syndrome),
a genetically transmitted inability to absorb the metallo
element. In the following, three examples for the efﬁcacy
of topical copper compounds are provided:
1. Based on the observation that topical applications of
copper salicylate produced anti-inﬂammatory effects
in humans volunteers, in certain countries (e.g.,
Australia), ethanolic Cu(II) salicylate-containing prep-
arations (Alcusal) are available over the counter for
1 RCC, 2002. Determination of the partition coefﬁcient (n-octanol/
water) of copper tripeptide-1 (PC 1044). RCC Ltd, Environmental
Chemistry & Parmaceutical Division; CH-4452 Ittingen/Switzerland.
Skin penetration of a copper tripeptide 83
123human use to alleviate arthritic pain [43], an example
of synergism between Cu (II) and an AI drug.
2. A chlorophyllin copper complex (CCC), derived from
chlorophyll by replacing the chelated magnesium with
copper, has anti-inﬂammatory and antimicrobial prop-
erties, as well as a marked stimulating effect on
epithelial cell growth rates and cell regeneration. First
established in tissue culture studies, these ﬁndings
were conﬁrmed clinically through wound healing and
deodorizing characteristics observed in animals and
humans [44]. Administered orally, CCC is classiﬁed as
a safe and effective internal deodorant by the US FDA
[45].
3. In order to document the tolerability of metallic copper
which must be oxidized in contact with the skin in
order to penetrate, Gorter examined absorption and
tolerance of metallic copper-containing ointments on
human volunteers over a period of several weeks.
Copper analysis in serum showed that levels had
increased signiﬁcantly above control levels, without
overt untoward effects, either in the skin or system-
ically, following application of ointments containing
up to 20% of the metal in its elemental form [46]. It
is well established that the Kp of organic chemicals is
determined by their lipophilicity and size [47]. This is
also likely to apply to (transition) metals complexed
with ligands subject to changes in pH and other
parameters in the skin with depth [48], which deter-
mine ionization as well as availability of ligands and
lipophilicity. Copper, a transition metal of variable
oxidation state, has the ability to form complexes with
different geometries and stability.
Similar to most transition metals, the mechanism by
which copper complexes permeate skin is little understood.
While copper distribution in the tissues analyzed resulted
in remarkably high stratum corneum retention, through that
barrier it also reached the highest values in the receptor
ﬂuid. Under present study conditions, signiﬁcant passive
transport of the copper species across separate skin strata of
differing barrier properties seems to indicate the various
potential routes of passage from the surface of the skin into
the subepidermal or dermal tissue: the appendageal, the
inter- and the intra-cellular pathways. Further, an addi-
tional factor appeared to determine the results obtained:
intrinsic complex rearrangement in the various skin com-
partments leading to retention and diffusion of copper ion
as a function of ligand. An undetermined part of copper
might transit through the skin as the undissociated original
tripeptide, and another might diffuse bound to endogenous
amino acids of higher complex stability constants such as
the histidinate [21], the predominant copper complex in
plasma, with cystinate as the secondary ligand.
Studies with labeled ligands (i.e., radio-labeled) may
help with further understanding the complex skin pene-
tration behavior of copper complexes. In the present study,
only diffusion followed by copper analysis on isolated or
separated tissue strata allowed a measure of insight.
Conclusions
Quantitativeassessmentofskinpenetrationandspecifyingthe
actualpenetration mechanismfor a copperpeptide isdifﬁcult
duetopossibleligandexchangesduringdiffusion.Theresults
described here, however, show that a topical organic copper
complex such as GHK-Cu may be an alternative to copper
delivery by injection, also potentially providing a skin reser-
voirlikelytobecomeavailableovertime.Thiseffectwarrants
further development towards transdermal delivery of the AI
agent, especially when considering GHK, a nature-identical
carrier tripeptide [18]. Several laboratories in the past
had demonstrated local and systemic AI activity of copper
compounds by oral, ip, iv, and particularly subcutaneous
administration. Having shown permeation of the skin barrier
by GHK-Cu in a therapeutically effective dose here, appli-
cationoftheprincipaltotransdermaldosingnowmaybecome
a realistic alternative to current, traditional routes and agents,
however. Taking our results a step further, controlled release
of copper for AI therapy using patch technology could be
optimized with well-designed formulations. The fact that a
deﬁcitinthatessentialelementmaybesigniﬁcantlycorrected
by choosing appropriate cupriphores is a signiﬁcant outcome
ofourendeavourstowardsalleviatingrheumatoidarthritisand
similarmusculoskeletalconditionsoftenafﬂictingthegeneral
population.
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